Klotz L (2008) Active surveillance for prostate cancer: trials and tribulations. World J Urol 26: 437–442
Parker C et al. (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94: 1361–1368
Klotz L (2005) Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2: 136–142
Barqawi AB and Crawford ED (2007) The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J 13: 313–317
Polascik TJ and Mouraviev V (2008) Focal therapy for prostate cancer. Curr Opin Urol 18: 269–274
Eggener SE et al. (2007) Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178: 2260–2267
Onik G (2004) The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technol Cancer Res Treat 3: 365–370
Poissonnier L et al. (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51: 381–387
Uchida T et al. (2006) Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 13: 228–233
Shariat SF et al. (2005) Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 65: 260–267
Korbelik M (2006) PDT-associated host response and its role in the therapy outcome. Lasers Surg Med 38: 500–508
Von Tappeiner H and Jodlbauer A (1907) The sensitizing action of fluorescent substances. An overall account of investigations on photodynamic phenomena [German]. Leipzig FCW Vogel
Lou PJ et al. (2004) Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 91: 441–446
Bown SG et al. (2002) Photodynamic therapy for cancer of the pancreas. Gut 50: 549–557
Gold MH (2007) Acne vulgaris: lasers, light sources and photodynamic therapy—an update 2007. Expert Rev Anti Infect Ther 5: 1059–1069
Wormald R et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD002030. 10.1002/14651858.CD002030.pub3
Huang Z et al. (2006) Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg Med 38: 672–681
Trachtenberg J et al. (2008) Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 102: 556–562
Trachtenberg J et al. (2007) Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178: 1974–1979
Haider MA et al. (2007) Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 244: 196–204
Gross S et al. (2003) Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 9: 1327–1331
Fleshker S et al. (2008) Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate. Photochem Photobiol 84: 1231–1237
Wink M et al. (2008) Contrast-enhanced ultrasound and prostate cancer: a multicentre European research coordination project. Eur Urol 54: 982–993
Pantelides ML et al. (1990) Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland. J Urol 143: 398–401
Chen Q et al. (1993) Photodynamic therapy in prostate cancer: optical dosimetry and response of normal tissue. Proc SPIE 1881: 231–235
Whitehurst C et al. (1994) In vivo laser light distribution in human prostatic carcinoma. J Urol 151: 1411–1415
Lee LK et al. (1995) In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem Photobiol 62: 882–886
Lee LK et al. (1999) An interstitial light assembly for photodynamic therapy in prostatic carcinoma. BJU Int 84: 821–826
Zhu TC et al. (2005) Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy. Photochem Photobiol 81: 96–105
Li J and Zhu TC (2008) Determination of in vivo light fluence distribution in a heterogeneous prostate during photodynamic therapy. Phys Med Biol 53: 2103–2114
Yu G et al. (2006) Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol 82: 1279–1284
Zhu TC et al. (2005) Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B 79: 231–241
Finlay JC et al. (2006) Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 82: 1270–1278
Moore C et al. (2006) A clinical evaluation of the optical characteristics of the prostate in men with prostate cancer [abstract #433]. Eur Urol 5 (Suppl): 131
Johansson A et al. (2007) Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate. Med Phys 34: 4309–4321
Altschuler MD et al. (2005) Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm. Med Phys 32: 3524–3536
Thompson MS et al. (2005) Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements. Appl Opt 44: 4023–4031
Jankun J et al. (2005) Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU Int 95: 1237–1244
Windahl T et al. (1990) Photodynamic therapy of localised prostatic cancer. Lancet 336: 1139
Nathan TR et al. (2002) Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 168: 1427–1432
Chang SC et al. (1996) Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer 67: 555–562
Chang SC et al. (1997) Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate 32: 89–98
Moore CM et al. (2006) Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med 38: 356–363
Zaak D et al. (2003) Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer—preliminary results. Medical Laser Application 18: 91–95
Hsi RA et al. (2001) Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res 7: 651–660
CAS PubMed Google Scholar
Pinthus JH et al. (2006) Photodynamic therapy for urological malignancies: past to current approaches. J Urol 175: 1201–1207
Verigos K et al. (2006) Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 25: 373–387
Patel H et al. (2008) Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res 14: 4869–4876
Zhu TC et al. (2003) In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 77: 81–88
Weersink RA et al. (2005) Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol 81: 106–113
Moore C et al. (2006) Vascular-targeted photodynamic therapy in organ confined prostate cancer–report of a novel photosensitiser [abstract #434]. Eur Urol 5 (Suppl): 131
Berdugo M et al. (2008) Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci 49: 1633–1644
Mazor O et al. (2005) WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 81: 342–351
Curnow A et al. (2006) Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med 38: 325–331
Togashi H et al. (2006) Fractionated photodynamic therapy for a human oral squamous cell carcinoma xenograft. Oral Oncol 42: 526–532
Dolmans DE et al. (2002) Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res 62: 4289–4294
CAS PubMed Google Scholar
Bisland SK et al. (2004) Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 80: 22–30
Renno RZ et al. (2004) Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-s2. Arch Ophthalmol 122: 1002–1011
Demidova TN and Hamblin MR (2004) Photodynamic therapy targeted to pathogens. Int J Immunopathol Pharmacol 17: 245–254
Embleton ML et al. (2005) Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus . Antimicrob Agents Chemother 49: 3690–3696
Embleton ML et al. (2004) Antibody-directed photodynamic therapy of methicillin-resistant Staphylococcus aureus . Microb Drug Resist 10: 92–97
Savellano MD et al. (2005) Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 65: 6371–6379
Vrouenraets MB et al. (2002) Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro . Int J Cancer 98: 793–798
Sharman WM et al. (2004) Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 56: 53–76
Schneider R et al. (2005) Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg Med Chem 13: 2799–2808
Ichikawa K et al. (2004) PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy. Biol Pharm Bull 27: 443–444
Hamblin MR et al. (2003) Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy. Br J Cancer 89: 937–943
van Nostrum CF (2004) Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv Drug Deliv Rev 56: 9–16
Chen X et al. (2004) Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells. Biochemistry 43: 10918–10929
Hamblin M et al. (2000) Scavenger-receptor targeted photodynamic therapy. Photochem Photobiol 72: 533–540
